Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic

Abstract

The overview is presented of results of I. line treatment of patients with advanced NSCLC using pemetrexed, erlotinib, gefitinib and bevacizumab. All patients treated in the Czech Republic are included from the start of use of the particular drug up to March 18th, 2013.

Keywords

• NSCLC
• I. line treatment
• pemetrexed
• erlotinib
• gefitinib
• bevacizumab